Advertisement
UK markets close in 6 hours 50 minutes

  • FTSE 100

    8,109.32
    +30.46 (+0.38%)
     

  • FTSE 250

    19,797.81
    +195.83 (+1.00%)
     

  • AIM

    755.81
    +2.69 (+0.36%)
     

  • GBP/EUR

    1.1658
    +0.0001 (+0.01%)
     

  • GBP/USD

    1.2532
    +0.0021 (+0.17%)
     

  • Bitcoin GBP

    51,383.37
    +476.26 (+0.94%)
     

  • CMC Crypto 200

    1,389.49
    -7.04 (-0.50%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    83.73
    +0.16 (+0.19%)
     

  • GOLD FUTURES

    2,358.90
    +16.40 (+0.70%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,046.40
    +129.12 (+0.72%)
     

  • CAC 40

    8,040.15
    +23.50 (+0.29%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Roche lung cancer pill gets reprieve in UK reversal

Reuters - UK Focus

LONDON, April 4 (Reuters) - Britain's health cost watchdog NICE (Milan: NICE.MI - news) on Friday reversed an earlier decision to limit the use of Roche's Tarceva cancer pill on the state health service in a move the drugmaker said would help around 2,000 patients a year.

New draft guidance from the National Institute for Health and Clinical Excellence (NICE) now backs use of Tarceva for people with non-small-cell lung cancer that has progressed after chemotherapy in wider circumstances than originally suggested.

NICE said its decision to maintain Tarceva access followed new evidence on the clinical and cost effectiveness of the drug, and also took into account the side-effect profile of the chemotherapy alternative. (Reporting by Ben Hirschler. Editing by Jane Merriman)